Supplemental Material




Figure S1.

Endocardial cushion development in wild type embryos

A: At E10,5 endocardial cells have migrated into the septal cushion (Sc) (blue) and parietal cushion (Pc) (purple). These cushions remained connected by a transitional zone (Tz) (cyan), a thin region of cardiac jelly sparsely populated by cells. B: The Pc and Sc enlarged at E11.5 whereas the transitional zone remained sparsely populated. C: At E12.5 the transitional zone was positioned at the site of the commissure between the left coronary leaflet (LC) and non-coronary leaflet (NC). The NC (yellow) was separated from the Pc. Myocardial cells were NKX2.5 positive (brown) . Scale bar is 50µm.




Figure S2.

NKX2.5⁺/TROPOMYOSIN cells represents ISL1⁺ second heart field cells contributing to the outflow tract.

A-E: Immuno-fluorescent images showing co-expression of NKX2.5 and ISL1 in second heart field cells contributing to the formation of the outflow tract in E11.5 wild type embryos. Colour scheme: Anti-NKX2.5 (red), Anti-ISL1 (green), Anti-TROPOMYOSIN (grey), DAPI was used as a nuclear staining (blue). Scale bar: 50µm.





Figure S3.



A-E: NKX2.5⁺/TROPOMYOSIN second heart field cells migrate into the cushions during development and contribute directly to the formation of the aortic leaflets. Colour scheme immunofluorescent images: Anti-NKX2.5 (green), Anti-TROPOMYOSIN (grey), Nuclei were stained with DAPI (blue). Colour scheme imunnohistological images: Anti-NKX2.5 (brown), nuclei are counterstained using hematoxine eosine (HE). Scale bar: 50µm.




Figure S4.

Cushion volume is not affected in Nos3^{\prime} embryos during stages E10.5 to E12.5 of embryonic development

A,B: Total cushion volume analysis indicated no differences (p> 0.05) in total volume of septal (A) and parietal (B) cushions between wild type and $Nos3^{-1}$ embryos during development. Close examination also showed no difference in the cellular fractions of the septal and parietal cushions nor the acellular fractions between wild type and $Nos3^{-1}$ embryos at stages E10.5 to E12.5. C: Myocardial volume analysis established that $Nos3^{-1}$ embryos have an equal heart size compared to wild type embryos. Data are mean \pm s.d. Analysis was performed using two tailed student T test.




Figure S5.

Aortic leaflets have unique cell lineage distributions

A-F: Detection of NKX2.5 positive cells negative for TROPOMYOSIN indicated direct contribution of second heart field cells to the non-coronary aortic and non-facing pulmonary leaflet in wild type embryos at E12.5. NKX2.5⁺/TROPOMYOSIN⁻ cells show no overlap with the *Tie2Cre* endothelial (A,D; green) or *Wnt1Cre* neural crest (B,E; green) lineages but do overlap with *Mef2cCre* second heart field derived cells (C,F; green). Dots indicate endothelial lining(white). Color scheme: TROPOMYOSIN (grey), DAPI (blue), NKX2.5 (red), Lineage-Cre derived GFP (green). Scale bar: 50µm




Figure S6.

Total leaflet volume is not affected in Nos3^{-/-} embryos.

Volume analysis of aortic leaflets in the aortic valve shows equal volume in wild type and $Nos3^{-/-}$ embryos.LC: left coronary leaflet, RC: right coronary leaflet, NC: non-coronary leaflet. Data are mean \pm s.d. Analysis was performed using two tailed student T test.




Figure S7.

Extracardial neural crest and second hear field population are not affected by Nos3 mutation.

A:D immuno-fluorescent images of extracardial NKX2.5⁺/TROPOMYOSIN⁻ second heart field (SHF) (yellow) and AP2A neural crest cell (green) populations in wild type (A,C) and *Nos3^{-/-}* (B,D) embryos at stage E11.5 when migration into the cushions has been initiated. E-F: 3D reconstruction of extracardial neural crest (green) and SHF populations (yellow) show similar localization in both wild type and *Nos3^{-/-}* embryos. G-H: Volume analysis of extracardial populations shows no difference (P > 0.05) between SHF cells (G) and neural crest cells (H) between wild type and *Nos3^{-/-}* at E11.5. Colour scheme: Anti-NKX2.5 (yellow), Anti-AP2A (Green), Anti-TROPOMYOSIN (red), Nuclei were stained with DAPI (blue). Data are mean ± s.d. Analysis was performed using two tailed student T test. Scale bars: 50µm

Fwd_Cre	ATG-GAT-TTC-CGT-CTC-TGG-TG
Rev_Cre	TTG-CCC-CTG-TTT-CAC-TAT-CC
Nos3_Mut_oIMR8963	AAT TCG CCA ATG ACA AGA CG
Nos3_WT_oIMR9357	AGG GGA ACA AGC CCA GTA GT
Nos3_Common_oIMR9358	CTT GTC CCC TAG GCA CCT CT
mTmG_WT_oIMR9021	CCG AAA ATC TGT GGG AAG TC
mTmG_Mut_22163	CGG GCC ATT TAC CGT AAG TTA T
mTmG_Common_oIMR9020	AAG GGA GCT GCA GTG GAG TA

Table S1. Primers used for genotyping

Primary Antibodies	Manufacturer	Dilutions	
Nkx2.5	Santa Cruz SC-8697	1/4000	
eGFP	Abcam ab13970	1/500	
Tropomyosin	Sigma-Aldrich Chemie T9283	1/500	
PECAM1	Santa Cruz sc-1506-R	1/500	
ΑΡ2α	GeneTex GTX62588	1/2000	
Secondary Antibodies	Manufacturer	Dilutions	
Horse Anti-Goat-Biotin	Vector labs BA-9500	1/200	
HRP~Streptavidine - (PO)	Agilent P039701	1/200	
Alexa Fluor488~Goat anti- Chicken IgY (H+L)	Thermo Scientific A-11039	1/200	
Alexa Fluor 594~Donkey Anti-Mouse IgG (H+L)	Life technologies A-21203	1/200	
Alexa Fluor 555~Donkey Anti-Rabbit IgG (H+L)	Life technologies A-31572	1/200	
Cy5-Biotin	LifeSpan Biosciences ab6975	1/200	

Table S2.

Antibodies used in this study

			Experimental Evaluation			
	Total embryos		Immuno-staining		3D Reconstructions	
Age	Wild Type	Nos3 ^{/-}	Wild Type	Nos3'-	Wild type	Nos3 ^{-/-}
E10.5	3	4	3	4	2	2
E11.0	7	6	7	6	1	0
E11.5	11	11	11	11	5	3
E12.0	4	2	4	2	1	0
E12.5	20	16	20	16	4	4
E13.5	14	11	14	11	2	1
E14.5	8	8	8	8	2	4
E15.5	3	8	3	8	0	0
E16.5	4	12	4	12	2	1

Table S3.

Number of embryos used in this study

Age	BAV in WT	BAV in Nos3 ^{-/-}	Other cardiovascular anomalies in WT	Other cardiovascular anomalies in <i>Nos3^{-/-}</i>
E12.5	0/20	4/16	0/20	0/16
E13.5	0/14	0/11	0/14	0/11
E14.5	0/8	2/8	0/8	0/8
E15.5	0/3	5/8	0/3	0/8
E16.5	0/4	4/12	0/4	0/12
Mean	0/49 (0%)	15/55 (27.27%)	0/49 (0%)	0/55 (0%)

Table S4.

Percentage of BAV found in wild type (WT) and Nos3^{-/-}.